Table 3.
Support measures and pharmacological treatments administered to patients admitted for SARS-COV-2
| Total patients (N = 74) | Patients with MIS-C (N = 45) | Patients without MIS-C (N = 29) | p | |
|---|---|---|---|---|
| Support measures. n/N (%) | ||||
| Oxygen therapy | 56/74 (79.7) | 36/45 (80) | 20/29 (69) | 0.215 |
| HFO | 26/74 (35.1) | 14/45 (31.1) | 12/29 (41.4) | 0.379 |
| NIV | 9/74 (12.2) | 2/45 (4.4) | 7/29 (24.1) | 0.026 |
| MV | 18/74 (24.3) | 6/45 (13.3) | 12/29 (41.4) | 0.005 |
| Neuromuscular blockade | 12/74 (16.2) | 3/45 (6.7) | 9/29 (31) | 0.009 |
| Ventilation in prone position | 9/74 (12.2) | 1/45 (2.2) | 8/29 (27.6) | 0.002 |
| V-V-ECMO | 1/74 (1.4) | 0/45 (0) | 1/29 (3.4) | 0.394 |
| A-V-ECMO | 1/74 (1.4) | 1/45 (2.2) | 0/29 (0) | 1 |
| NOi | 3/74 (4.1) | 0/45 (0) | 3/29 (10.3) | 0.057 |
| CRRT | 0/74 (0) | 0/45 (0) | 0/29 (0) | - |
| Transfusion of hemoderivatives | 14/74 (18.9) | 5/45 (11.1) | 9/29 (31) | 0.034 |
| Vasoactive drugs | 37/74 (50) | 30/45 (66.7) | 7/29 (24.1) | < 0.001 |
| Pharmacological therapies n/N (%) | ||||
| Antibiotic | 65/74 (87,8) | 42/45 (93.3) | 23/29 (79.3) | 0.020 |
| Lopinavir–ritonavir | 30/74 (40.5) | 18/45 (40) | 12/29 (41.4) | 0.857 |
| Remdesivir | 5/74 (6.8) | 0/45 (0) | 5/29 (17.2) | 0.006 |
| Hydroxychloroquine | 43/74 (58.1) | 25/45 (55.6) | 18/29 (62.1) | 0.550 |
| Corticosteroids | 49/74 (66.2) | 36/45 (80) | 13/29 (44.8) | 0.003 |
| Immunoglobulins | 25/74 (33.8) | 23/45 (51.1) | 2/29 (6.9) | < 0.001 |
| Tocilizumab | 17/74 (23) | 11/45 (24.4) | 6/29 (20.7) | 0.871 |
Comparison of patients with MIS-C and without MIS-C
HFO high-flow rate oxygen, NIV noninvasive ventilation, MV invasive mechanical ventilation, V-V-ECMO veno-venous extracorporeal membrane oxygenation, V-A ECMO veno-arterial extracorporeal membrane oxygenation, NOi Inhaled nitric oxygen, CRRT continuous renal replacement therapy